|Bid||1.71 x 1000|
|Ask||3.03 x 4000|
|Day's Range||2.1600 - 2.5000|
|52 Week Range||1.6000 - 4.7500|
|Beta (3Y Monthly)||2.13|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.25|
Biomerica, Inc. (BMRA) today reported net sales of $1,500,791 for the three months ended November 30, 2018, compared to $1,613,636 for the same period in the previous year. Net sales were $2,773,661 for the six months ended November 30, 2018 compared to $3,058,119 for the same period in last year. The Company ended the quarter with approximately $798,000 in backlog for open orders, which were not shipped as of November 30, 2018. Biomerica announced a net loss for the three months ended November 30, 2018 of $477,244, or $0.05 per share, versus a net loss of $268,661, or $0.03 per share, in the previous fiscal year during the same quarter. The net loss for the six months ended November 30, 2018 was $928,984, or $0.10 per share, compared to net loss of $475,720, or $0.06 per share in the prior fiscal year.
Biomerica, Inc. (BMRA) announced that is has signed a three year agreement with Medline Industries for the distribution of Biomerica’s EZ Detect™ colorectal disease screening test designed to help identify an early warning sign of colorectal cancer. The EZ Detect colorectal screening test is the simplest at home test to detect fecal occult (hidden) blood, an early warning sign of colorectal cancer. With over 18,000 employees worldwide, 1,600 direct sales reps and $10.2 billion in sales, Medline Industries is ranked 32 on the Forbes list of largest private companies. Medline is the largest privately held manufacturer and distributor of medical supplies uniquely positioned to provide products, education and support across the continuum of care (from large healthcare systems and independent physician practices to home health patients and their families).
NEW YORK, Nov. 16, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Every investor in Biomerica Inc (NASDAQ:BMRA) should be aware of the most powerful shareholder groups. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to Read More...
Biomerica (BMRA) reported financial results for their fiscal 2019 first quarter ending August 31, 2018. The weakness related almost entirely to Europe and the U.S., which were both down double-digit percentages from the year-earlier period. Fortunately Asia, which accounts for ~50% of total revenue saw solid gains from both comparable periods, limiting the yoy total revenue slide and pushing it into positive territory sequentially.
Zero-debt allows substantial financial flexibility, especially for small-cap companies like Biomerica Inc (NASDAQ:BMRA), as the company does not have to adhere to strict debt covenants. However, it also faces higher Read More...
Biomerica (BMRA) reported financial results for their fiscal 2018 fourth quarter ending May 31, 2018. While our model had revenue inching up 6% for the full-year reflecting an expectation that rebounding sales in Asia would more than offset ongoing softness in both Europe and the U.S., that was far from the case. Instead, the nearly across-the-board (Latin America was the sole bright spot) weakness in Q4, which most notably included a 42% yoy contraction in Asia, resulted in annual sales falling almost 4%.
Biomerica Inc’s (NASDAQ:BMRA): Biomerica, Inc., together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions worldwide. WithRead More...
Today, I will be analyzing Biomerica Inc’s (NASDAQ:BMRA) recent ownership structure, an important but not-so-popular subject among individual investors. Ownership structure of a company has been found to affect shareRead More...
Biomerica (BMRA) reported financial results for their fiscal 2018 third quarter ending February 28, 2018. Revenue, down 8% yoy and 15% qoq, was softer than we were expecting with both Europe and U.S. sales contributing to the miss. • Fiscal Q3 has historically been a relatively strong quarter for BMRA’s U.S. business – and while that proved to be true as compared to the first two quarters of 2018, on a prior years’ basis, domestic sales were relatively very weak – in fact, the lowest Q3 U.S. number since at least 2009.
For long-term investors, assessing earnings trend over time and against industry benchmarks is more beneficial than examining a single earnings announcement at a point in time. Investors may find myRead More...
Biomerica Inc’s (NASDAQ:BMRA): Biomerica, Inc., together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions worldwide. TheRead More...
Q2 2018 Results: Revenue, particularly in Asia, was very strong. Biomerica (BMRA) reported financial results for their fiscal 2018 second quarter ending November 31, 2017. And just prior to releasing Q2 results, they made several potentially very substantive announcements related to operational progress of both their legacy business as well as to InFoods – the latter which prompted significant updates to our long-term revenue forecasts as well as to our price target.